Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04666-7 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Liam Wilson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada. liam.wilson@mail.mcgill.ca. Hauptthemen laut MEDLINE: Glioblastoma, Temozolomide, Bevacizumab, Brain Neoplasms. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada. liam.wilson@mail.mcgill.ca.
- Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada.
Zitieren
APA
Wilson, L., Atallah, A., & Romero, J. M. (2024). Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04666-7
Vancouver
Wilson L, Atallah A, Romero JM. Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04666-7
BibTeX
@article{Wilson2024,
author = {Wilson, Liam and Atallah, Aline and Romero, Joan Miguel},
title = {Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04666-7}
}
EUVIMED